Index · Artikel · Too many drug types are compromising heart health: doctors

Too many drug types are compromising heart health: doctors

2013-03-14 3
   
Advertisement
résumén">About 80 million Americans suffer from heart disease, the nation's No. 1 killer, and most are on multiple drugs. Some cardiologists think prescribing has gotten out of hand. The criticism was voiced by a number of leading heart doctors who atte
Advertisement

Too many drug types are compromising heart health: doctors


n">About 80 million Americans suffer from heart disease, the nation's No. 1 killer, and most are on multiple drugs.

Some cardiologists think prescribing has gotten out of hand.

The criticism was voiced by a number of leading heart doctors who attended the annual scientific sessions of the American College of Cardiology, held on March 9-11 in San Francisco. They said eliminating certain drugs could potentially improve care without compromising treatment. Evidence is growing that some medications are not effective.

Patients who need multiple daily doses of a given drug often fail to take them, said Dr. Steven Nissen, head of cardiology at the Cleveland Clinic and a past president of the ACC. "There is also the question about whether the benefits are additive."

Among the medications cardiologists are giving a second look: AbbVie's Niaspan, or prescription niacin, which aims to raise good cholesterol; so-called fenofibrate such as top-selling branded drug TriCor (also from AbbVie), which lowers blood fats called triglycerides; and beta-blockers, most of which are inexpensive, older generics.

'EAGER TO ADD, RELUCTANT TO TAKE AWAY'

A person who has had a heart attack typically leaves the hospital on a beta-blocker to slow the heart, an ACE inhibitor to reduce blood pressure, clopidogrel and aspirin to thin the blood and prevent clots, and a statin to reduce cholesterol, said Dr. Micah Eimer, a cardiologist with Northwestern Medicine in suburban Chicago.

"That's a minimum of five medications, and each one has a proven mortality benefit. It's practically malpractice if you don't prescribe those," Eimer said. "But we have no data on when it's advantageous to take (patients) off."

Many patients are on many more drugs, according to research by Dr. Harlan Krumholz, a Yale University professor of cardiology and public health. Using Medicare data, he found that heart failure patients, those whose hearts are too weak to pump blood sufficiently, were prescribed an average of 12 drugs; some were on 30.

"We are eager to add medicines and reluctant to take them away," said Krumholz, who heads the Yale-New Haven Hospital Center for Outcomes Research and Evaluation and is a frequent critic of how drugs are sold and used. "So people accrue medications over time."

Many drugs are prescribed widely, even though evidence they actually work is weak, he said.

Unexpected serious side effects arose in a huge study of a Merck & Co long-acting niacin drug aimed at raising good HDL cholesterol, according to data released at the conference on Saturday. [ID:nL1N0C11ZL] The study enrolled more than 25,000 people. Patients had significantly more bleeding and a higher number of infections than researchers had expected. A Merck spokesman said there "was nothing to add."

When it was announced that the drug, Tredaptive, had failed to prevent heart attacks, strokes and death in heart patients also taking drugs to lower bad LDL cholesterol, Merck said it would not seek U.S. approval and would stop selling it in the dozens of other countries where it was already available.

Fenofibrate, including AbbVie's TriCor, has also failed to show benefit in two separate studies, Krumholz said. The $2 billion-a-year drug is used to lower low-density lipoprotein, or LDL, the unhealthy cholesterol, and triglycerides and to raise high-density lipoprotein, or HDL, the healthy cholesterol.

AbbVie's cardiovascular products "help patients with abnormal cholesterol levels reach their cholesterol treatment goals," the company said in an emailed statement. "Physicians need to consider the results of clinical trials, available treatment guidelines, and each patient's cardiovascular and benefit/risk profile to determine the best possible treatment regimen."

Other drug companies including Sanofi, Bristol-Myers Squibb Co and Pfizer declined to comment.

BLOCK THAT BLOCKER?

Beta-blockers are absolutely necessary for some patients, said Dr. Sripal Bangalore, a cardiologist at New York University, but are probably prescribed too widely and for too long a period of time. Examining three distinct patient groups from a data registry of 44,000 patients, he said the drug did not reduce the risk of heart attack, stroke or death after 3.5 years.

Yet the American Heart Association (AHA) and American College of Cardiology guidelines recommend heart attack survivors take beta-blockers for at least three years. Those recommendations, several doctors noted, are based on data collected two decades ago. "We don't know if they are providing benefit for one year or three years," Bangalore said.

Today, blocked arteries are cleared right away with angioplasty, and the patient is typically put on a statin to keep harmful cholesterol from building up in the artery walls. For those whose hearts are not badly damaged, beta-blockers do not help.

Then there are blood thinners, like Warfarin, commonly used to treat some types of heart disease by preventing clots. Dr. Robert Harrington, a cardiologist at the Stanford School of Medicine, said patients were at risk of bleeding when they were on more than one. "We've had recent trials where we've gone from one to two to three agents," he said. "There's got to be a way to start peeling away, and maybe it's over a period of time, or as the clinical status changes."

MARKET SIDE EFFECTS

Clinical trials that have called into question the drugs' benefits have affected sales. Combined sales of AbbVie's TriCor and Trilipix were $1.4 billion in 2012, down from $1.7 billion in 2011. Sales of Niaspan were $911 million in 2012, down from $976 million in 2011.

Cowen and Co estimates the 13 main classes of drugs used to treat various types of cardiovascular disease had U.S. sales of almost $75 billion in 2011. The brokerage expects sales to shrink to about $59 billion in 2016 because of recent and looming patent expirations on branded products.

Even if doctors aggressively cut back the number of heart medicines they prescribe, however, it would have only a limited impact on drugmaker revenue because many would be the generic older drugs that are far cheaper, according to analyst Barbara Ryan, of Barbara Ryan Advisors.

Dr. Richard Stein, a professor of medicine at New York University and spokesperson for the AHA, estimated the average patient with heart disease truly needs to take from seven to nine pills each day in order to control the various risk factors, including cholesterol, high blood pressure and diabetes. Beyond that, he said, it makes sense to be restrictive.

"Doctors should look for combination pills if they can, and exclude pills that don't critically help patient care," he said. "To live your life taking that many pills, the danger is you'll stop taking the critical ones, because how many pills can you take several times a day?"

(Reporting by Debra Sherman; Additional reporting by Rans Pierson and Bill Berkrot; Editing by Jilian Mincer, Martin Howell and Prudence Crowther)

TOP

  • Day/
  • Week/
  • Original/
  • Recommand

Updated

  • Ist Allegra Blutdruck erhöhen?

    Ich nehme BP Medizin, Attenol, aber mein BP hat sich seit der Einnahme dieses Medikaments hoch. Auch ein rasendes Herz w / Herzklopfen. ----schneiden---- In Antwort auf die Marvell bei 2010-06-04 05.41 Nehmen Sie Allegra oder Allegra D? Allegra D kan
  • Ich dachte, ich die meisten technischen Begriffe rund um meine Rückenprobleme wusste?

    Ich weiß, ich Kompressionsfrakturen in meiner Wirbelsäule geplatzt. Ich weiß, auch die Begriffe, die Knochenfragmente im Spinalkanal ging bedeuten und komprimiert meine Schnur um 80%. weiß jemand, was "Es gibt auch Frakturen der linken Querfortsätze
  • Blocking "rogue gene" may stop cancer spread: study

    Blocking "rogue gene" may stop cancer spread: study
    LONDON British scientists have discovered a "rogue gene" which helps cancer spread around the body and say blocking it with the right kind of drugs could stop many types of the disease in their tracks. Researchers from the University of East Ang
  • Die bakterielle Infektion - Ist Augmentin 875 2x pro Tag gut genug für milde Divertikulitis?

    Ich habe anhaltende Probleme mit Divertikulitis hatte und in der Regel Cipro und Flagyl, wenn seine viel schlimmer. Ich sah einen neuen Gastro Arzt und er sagte, für eine mildere Infektion Ausbruch er schreibt nur Augmentin 875 2x pro Tag. Weiß jeman
  • ER crowding tied to higher death rates

    ER crowding tied to higher death rates
    NEW YORK (Reuters Health) - Rerouting ambulances away from overcrowded emergency rooms may be costing patients their lives, U.S. researchers say. For patients with heart attack, high levels of rerouting are tied to a three percent higher risk of deat
  • Kann norethindrone 5mg als birthcontrol eingesetzt werden?

    im 52 n glauben im prämenopausalen. dr nahm mich weg birthcontrol und setzte mich auf progestorone b / zwischen den Perioden von Blutungen. kann ich das als bc verwenden ?? ----schneiden---- In Antwort auf DzooBaby bei 2011-06-22 17.42 Ja. Dieses wir
  • "Der Bereich der Fettleibigkeit ist effektiv tot" (Morning Read)

    "Der Bereich der Fettleibigkeit ist effektiv tot" (Morning Read)
    Aktuelle medizinische Nachrichten und einzigartigen Business - Nachrichten für alle , die über die Healthcare - Industrie kümmert. FDA lehnt Contrave. Was es bedeutet : "Wenn es eine Pille in der aktuellen Ernte von experimentellen Gewichtsverlust Me
  • STERIS Kunden erhalten weitere sechs Monate für System 1 Übergang

    STERIS Kunden erhalten weitere sechs Monate für System 1 Übergang
    Die US - amerikanische Food and Drug Administration hat um sechs Monate eine Frist für die STERIS (erweiterte NYSE: STE ) Kunden den Übergang von seinem System 1 Sterilisator zu unterstützen, für die die FDA vor Zulassung 2 Jahre widerrufen. Gemäß de
  • Calisthenics - Was sind Calisthenics und wie Sie tun, um sie?

    Calisthenics - Was sind Calisthenics und wie Sie tun, um sie?
    Calisthenics ist ein Begriff, viele von uns wahrscheinlich vor Jahren und Jahren in der Turnhalle Klasse gehört ... ein Wort, das kann man sie zusammenzucken. Der Begriff Freiübungen bezieht sich auf Übungen, die in einer rhythmischen, systematische
  • ONE Die Veranstaltung startet am 11.09 Angst in Liebe verwandeln zu helfen

    ONE Die Veranstaltung startet am 11.09 Angst in Liebe verwandeln zu helfen
    In dem Bemühen , Angst in Liebe durch die Kraft der menschlichen Absicht zu verwandeln, hat Seattle Feuerwehrmann Erik Rechtsanwalt eine transformierende Ereignis ins Leben gerufen ONE Das Ereignis wird aufgerufen ( www.OneTheEvent.org ). Erik ist de